Resource impact statement
No significant resource impact is anticipated
We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,100 per 100,000 population).
This is because the ertugliflozin is an additional option alongside current treatment options and is similarly priced to alternative treatments.
Ertugliflozin is commissioned by clinical commissioning groups. Providers are NHS hospital trusts, community providers and primary care.
This page was last updated: